CBAY CymaBay Therapeutics Inc.

-0.01  -0%
Previous Close 6.48
Open 6.49
Price To Book 1.73
Market Cap 444,463,398
Shares 68,696,043
Volume 434,384
Short Ratio
Av. Daily Volume 1,564,173

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned - to be initiated by Kowa Pharmaceuticals.
Phase 3 top-line data due in 2021.
Primary biliary cholangitis (PBC)
Phase 2b top-line data noted reductions in liver fat that were not significant compared with placebo - June 11, 2019. 52-week histology results likely due 1H 2020.
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
  2. Bulls Walk the Market Up Slowly, but Keep One Eye on Fed
  3. Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more
  4. CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference
  5. CymaBay Therapeutics: What Investors Should Watch For
  6. What’s Been Dragging Down CymaBay Therapeutics Stock
  7. Intercept Pharmaceuticals, CymaBay’s and Viking’s Competitor
  8. What Analysts Recommend for CBAY and VKTX
  9. CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
  10. Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
  11. CymaBay Therapeutics Stock Plunged. Here’s Why It Could Be Time to Buy
  12. The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana
  13. CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?
  14. Here's Why CymaBay Therapeutics Collapsed Today
  15. How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares?
  16. CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors
  17. CymaBay Therapeutics Plummets 40% Following Liver Disease Data
  18. CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
  19. Steven Cohen Takes an Interest in CymaBay Therapeutics
  20. Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock